JB Pharma, led by CEO Nikhil Chopra, forecasts 12-14% revenue growth and aims to increase Ebitda margins by 27-28% in FY25. The growth is driven by a focus on chronic portfolio, CDMO business expansion, and upcoming acquisition of an ophthalmology drugs portfolio from Novartis. The company's financial performance in FY24 was strong with revenue reaching Rs 3,484 crore.